Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.

Disclosed are compositions and formulations of non-porcine lipase and methods of treatment and manufacture thereof.

A drug delivery device includes an enteric capsule enclosing an internal volume and a plurality of drug containing particles positioned within the internal volume. Each of the plurality of drug containing particles includes a matrix body and an active pharmaceutical ingredient (API) distributed within the matrix body. The plurality of drug containing particles are configured to penetrate tissue, such as intestinal mucosa.

The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

There is provided an alkali metal salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide and formulations thereof. This salt finds particular utility in the treatment or prevention of a disorder or condition ameliorated by the activation of AMPK.

Compositions and methods are provided for the prevention or treatment of RSV infection and SARS-CoV2 virus related infections, such as COVID-19 (2019-nCoV), in a human. The methods include administering one or more doses of a composition comprising an encapsulated nano-metal oxide (NMO) or nano-metal oxide chelate (NMO-Ch). The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. Particles or droplets contain material systems that include composite particles having a core and one or more shells that enclose the core. In this case, the shell is a nonlamellar amorphous material, and the internal matrix core contains a metal oxide or metal oxide chelate.

An orally administered solid dosage form drug for treating cancers, tumors or cell proliferative disorders contains a compound of the following structural formula I or II.

##STR00001##

Compositions and methods of treatment for multiple myeloma (MM) are disclosed that include a liposome with a lipid bilayer shell enclosing a fluid-filled center, a targeting moiety coupled to the outer surface of the shell, a treatment compound disposed within the lipid bilayer shell or within the fluid-filled center, and an efficacy-enhancing compound disposed within the lipid bilayer shell or within the fluid-filled center. In some embodiments, the targeting moiety is PSGL-1, the proteasome-inhibiting compound is bortezomib, and the BMME-disrupting agent is a CXCR4 inhibitor or ROCK inhibitor.

Compositions of SGLT2 inhibitors and their use for treating primary biliary cholangitis (PBC) are described here. The SGLT2 inhibitor compositions, including oral dosage forms, contain a therapeutically effective dose of a SGLT2 inhibitor for preventing, partially ameliorating or fully ameliorating symptoms of PBC, including of the hepatic encephalopathy, development of varices, jaundice, variceal bleeding cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.